Claims for Patent: 12,016,848

Summary for Patent: 12,016,848

Title:	Roflumilast formulations with an improved pharmacokinetic profile
Abstract:	An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
Inventor(s):	David Osborne
Assignee:	Arcutis Biotherapeutics Inc
Application Number:	US18/453,674
Patent Claims:	1. A topical roflumilast pharmaceutical composition comprising: (i) roflumilast in an amount of 0.05-1.0% w/w; (ii) water; (iii) a hydrophobic component; (iv) a solvent comprising diethylene glycol monoethyl ether; and (v) a surfactant; wherein said topical roflumilast composition is an emulsion, and wherein said topical roflumilast composition has a roflumilast absorption profile that produces in a patient following administration, a plasma concentration time curve having a delayed Tmax relative to oral administration of roflumilast. 2. The composition of claim 1, wherein the surfactant comprises a blend of ceteraryl alcohol, dicetyl phosphate, and ceteth-10 phosphate. 3. The composition of claim 1, wherein the hydrophobic component comprises petrolatum. 4. The composition of claim 2, wherein the hydrophobic component comprises petrolatum. 5. The composition of claim 1, wherein said Tmax is between about 3 and 9 hours at steady state. 6. The composition of claim 2, wherein said Tmax is between about 3 and 9 hours at steady state. 7. The composition of claim 3, wherein said Tmax is between about 3 and 9 hours at steady state. 8. The composition of claim 4, wherein said Tmax is between about 3 and 9 hours at steady state. 9. The composition of claim 5, wherein said Tmax is between about 8 and 9 hours at steady state. 10. The composition of claim 6, wherein said Tmax is between about 8 and 9 hour at steady state. 11. The composition of claim 7, wherein said Tmax is between about 8 and 9 hours at steady state. 12. The composition of claim 8, wherein said Tmax is between about 8 and 9 hours at steady state.